GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Innovent Biologics 1801.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

86.45

+0.12%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥15.18bn

FY2016FY2025

Net income

CN¥946.8m

FY2016FY2025

Free cash flow

CN¥10.84bn

FY2016FY2025

Shareholders' equity

CN¥22.54bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥15.18bnCN¥9.42bnCN¥6.21bnCN¥5.30bnCN¥4.97bnCN¥3.84bnCN¥1.05bnCN¥9.5mCN¥18.5mCN¥32.1m
Research and developmentCN¥3.05bnCN¥2.68bnCN¥2.23bnCN¥3.34bnCN¥2.88bnCN¥1.85bnCN¥1.29bnCN¥1.22bnCN¥611.9mCN¥384.7m
Operating incomeCN¥853.8m−CN¥755.9m−CN¥1.68bn−CN¥3.63bn−CN¥3.48bn−CN¥790.4m−CN¥1.66bn−CN¥5.80bn−CN¥750.1m−CN¥495.2m
Net incomeCN¥946.8m−CN¥94.6m−CN¥1.03bn−CN¥2.54bn−CN¥3.65bn−CN¥998.4m−CN¥1.72bn−CN¥5.77bn−CN¥562.3m−CN¥504.2m
Diluted earnings per share0.53-0.06-0.65-1.67-2.50-0.71-1.36-11.02-5.54-0.45

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥43.48bnCN¥25.14bnCN¥24.01bnCN¥20.47bnCN¥18.90bnCN¥11.83bnCN¥7.23bnCN¥6.11bnCN¥2.46bnCN¥2.82bn
Cash and short-term investmentsCN¥21.23bnCN¥9.17bnCN¥12.77bnCN¥10.67bnCN¥10.49bnCN¥8.12bnCN¥4.70bnCN¥4.53bnCN¥1.32bnCN¥1.80bn
Total liabilitiesCN¥20.02bnCN¥9.87bnCN¥9.43bnCN¥7.98bnCN¥6.88bnCN¥3.06bnCN¥2.47bnCN¥1.92bnCN¥4.08bnCN¥3.77bn
DebtCN¥3.29bnCN¥2.83bnCN¥3.62bnCN¥3.23bnCN¥2.50bnCN¥1.21bnCN¥865.1mCN¥792.0mCN¥510.0mCN¥500.0m
Shareholders' equityCN¥22.54bnCN¥15.27bnCN¥14.58bnCN¥12.49bnCN¥12.02bnCN¥8.78bnCN¥4.76bnCN¥4.19bn−CN¥1.94bn−CN¥1.38bn
Shares outstanding1,788m1,632m1,584m1,515m1,461m1,403m1,263m524m102m1,118m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥11.64bnCN¥1.29bnCN¥172.0m−CN¥2.23bn−CN¥2.36bn−CN¥307.7m−CN¥1.66bn−CN¥1.02bn−CN¥492.3m−CN¥363.0m
Capital spending−CN¥795.2m−CN¥1.71bn−CN¥1.61bn−CN¥1.61bn−CN¥2.15bn−CN¥771.8m−CN¥365.9m−CN¥312.7m−CN¥91.0m−CN¥58.4m
Free cash flowCN¥10.84bn−CN¥418.4m−CN¥1.44bn−CN¥3.84bn−CN¥4.51bn−CN¥1.08bn−CN¥2.03bn−CN¥1.33bn−CN¥583.2m−CN¥421.4m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥9.89bnCN¥8.25bnCN¥6.93bnCN¥5.47bnCN¥3.95bnCN¥3.50bnCN¥3.14bnCN¥2.70bn
Operating incomeCN¥2.19bn−CN¥9.8mCN¥863.6m−CN¥15.2m−CN¥740.7m−CN¥960.5m−CN¥836.6m−CN¥1.95bn
Net incomeCN¥1.44bn−CN¥24.2mCN¥971.0mCN¥298.0m−CN¥392.6m−CN¥888.8m−CN¥161.9m−CN¥1.43bn
Diluted earnings per share0.80-0.010.540.18-0.24-0.56-0.10-0.94
Cash from operations—CN¥11.24bnCN¥504.0mCN¥1.50bn−CN¥215.0mCN¥896.0m−CN¥724.0m−CN¥1.29bn
Capital spending—−CN¥265.0m−CN¥48.0m−CN¥266.0m−CN¥699.0m−CN¥606.0m−CN¥695.0m−CN¥544.0m
Free cash flow—CN¥10.98bnCN¥456.0mCN¥1.24bn−CN¥914.0mCN¥290.0m−CN¥1.42bn−CN¥1.84bn
Total assetsCN¥48.42bnCN¥43.48bnCN¥27.46bnCN¥21.60bnCN¥20.30bnCN¥20.63bnCN¥20.83bnCN¥20.47bn
Cash and short-term investmentsCN¥23.27bnCN¥21.23bnCN¥11.10bnCN¥7.88bnCN¥8.63bnCN¥10.97bnCN¥8.90bnCN¥9.62bn
DebtCN¥641.3mCN¥3.29bnCN¥3.93bnCN¥2.83bnCN¥3.35bnCN¥3.62bnCN¥4.02bnCN¥3.76bn
Shareholders' equityCN¥24.14bnCN¥22.54bnCN¥16.78bnCN¥13.12bnCN¥12.43bnCN¥12.53bnCN¥12.55bnCN¥12.49bn

Financial ratios

Data as of 7 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin5.6%-8.0%-27.1%-68.5%-70.0%-20.6%
Net margin6.2%-1.0%-16.6%-47.8%-73.5%-26.0%
Return on equity4.2%-0.7%-8.2%-20.3%-30.4%-11.4%
Return on assets2.2%-0.4%-5.0%-12.4%-19.3%-8.4%
Free cash flow yield5.9%1.8%1.0%-0.3%-0.1%0.3%
Revenue growth38.4%51.8%36.2%6.7%11.1%266.9%
Earnings growth-959.7%-90.8%-52.8%-30.6%214.3%-42.0%
Current ratio2.62x2.35x3.00x3.29x3.79x6.37x
Debt to equity0.14x0.22x0.28x0.29x0.23x0.13x
Equity ratio51.8%60.7%60.7%61.0%63.6%74.2%
Interest coverage9.46x-11.17x-17.03x-30.71x-47.84x-11.56x
R&D as a share of sales20.1%28.5%35.9%63.0%58.0%48.2%
Buybacks as a share of market value-9.5%-3.0%-4.5%-3.7%-4.1%-11.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue42.0%31.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings126.6-555.3-58.0-17.6-17.0-101.4-17.1-1.9
Price to sales7.95.69.68.412.526.328.1—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.